Related Experiment Video

Updated: Nov 23, 2025

Steps for the Autologous Ex vivo Perfused Porcine Liver-kidney Experiment
10:15

Steps for the Autologous Ex vivo Perfused Porcine Liver-kidney Experiment

Published on: December 18, 2013

7.7K

Circulating hepassocin level in patients with stable angina is associated with fatty liver and renal function

I-Ting Tsai1,2, Wei-Chin Hung3,2, Yung-Chuan Lu4,5

  • 1Department of Emergency, E-Da Hospital, Kaohsiung 82445 Taiwan.

International Journal of Medical Sciences
|January 4, 2021
PubMed

Insights

Plasma hepassocin levels are linked to fatty liver and reduced kidney function in stable angina patients. Higher hepassocin may contribute to the development of fatty liver and chronic kidney disease (CKD).

Area of Science:

  • Cardiology
  • Nephrology
  • Hepatology

Background:

  • Chronic kidney disease (CKD) is a significant risk factor for coronary artery disease and often co-occurs with hepatic steatosis.
  • Hepassocin, a novel hepatokine, is implicated in hepatic steatosis and insulin resistance.
  • The specific role of hepassocin in renal function remains largely undetermined.

Purpose of the Study:

  • To investigate the association between plasma hepassocin levels and fatty liver.
  • To examine the relationship between plasma hepassocin levels and renal function status.
  • To explore these associations in patients diagnosed with stable angina.

Main Methods:

  • Plasma hepassocin levels were quantified using enzyme-linked immunosorbent assays (ELISA) in 395 stable angina patients.
  • Renal function was assessed by estimated glomerular filtration rate (eGFR).
  • Fatty liver was diagnosed via ultrasonography and the Fibrosis-4 (FIB-4) index.

Main Results:

  • Higher hepassocin tertiles correlated with increased prevalence of fatty liver, elevated waist-to-hip ratio, and higher counts of neutrophils and monocytes.
  • Increasing hepassocin levels were associated with higher uric acid, blood urea nitrogen, and C-reactive protein, alongside lower eGFR, hemoglobin, and albumin.
  • Multivariate regression analysis revealed a significant independent negative association between plasma hepassocin levels and eGFR.

Conclusions:

  • Circulating hepassocin levels in patients with stable angina are associated with the presence of fatty liver and impaired renal function.
  • Elevated plasma hepassocin may play a role in the pathological processes underlying fatty liver and CKD.
  • Further research is warranted to elucidate the precise mechanisms linking hepassocin to these conditions.

Keywords:
Hepassocinfatty liverrenal functionstable angina

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

21.9K
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

16.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
83
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
105
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
353
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
111
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
130
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
248